Klaus Moosmayer - Novartis Executive
| NVSEF Stock | USD 116.60 8.74 8.10% |
Executive
Dr. Klaus Moosmayer, Ph.D., was Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee of Novartis Inc. since December 1, 2018. He previously was Chief Compliance Officer of Siemens AG, a position he held from 2014. During his 18year career at Siemens, he also served as chief counsel compliance, compliance operating officer and corporate legal counsel. Before joining Siemens, he practiced law in Germany, specializing in whitecollar crime, litigation and business law. Dr. Moosmayer received his doctor of jurisprudence from the University of Freiburg in Germany and is internationally recognized in the field of compliance. He is chair of the AntiCorruption Task Force of the Business and Industry Advisory Committee at the Organization for Economic Cooperation and Development cofounder and chair of the European Chief Compliance and Integrity Officers Forum former cochair of the B20 Integrity Compliance Task Force under the G20 presidency of Argentina and former chair of the task force under the G20 presidency of Germany. Dr. Moosmayer lectures on compliance at the University of St.Gallen in Switzerland. since 2018.
| Age | 55 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 41 61 324 1111 |
| Web | https://www.novartis.com |
Novartis Management Efficiency
The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Pr Belvisi | AstraZeneca PLC ADR | N/A | |
| Gigi DeGuzman | Scilex Holding | N/A | |
| Roy Papatheodorou | Sanofi ADR | 47 | |
| Rebecca Edwards | Organon Co | N/A | |
| Rachel Stahler | Organon Co | 49 | |
| Linda MD | Novartis AG ADR | 61 | |
| Charles Sawyers | Novartis AG ADR | 62 | |
| Andrew Barnett | AstraZeneca PLC ADR | N/A | |
| Vasant MD | Novartis AG ADR | 49 | |
| Stefan Oelrich | Bayer AG | 55 | |
| Sumant Rajendran | Scilex Holding | N/A | |
| Etienne Jousseaume | Novartis AG ADR | N/A | |
| Werner Baumann | Bayer AG | 61 | |
| Jeffrey Pott | AstraZeneca PLC ADR | N/A | |
| Sloan Simpson | Novartis AG ADR | N/A | |
| Karenann Terrell | GlaxoSmithKline PLC ADR | 58 | |
| William Winters | Novartis AG ADR | 60 | |
| Joseph Morrissey | Organon Co | 59 | |
| Jennifer Halchak | Organon Co | N/A | |
| Adrian Kemp | AstraZeneca PLC ADR | N/A | |
| Susan MD | AstraZeneca PLC ADR | 59 | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 |
Novartis AG Leadership Team
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Saynor, Chief Sandoz | ||
| Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee | ||
| MarieFrance Tschudin, Pres Officer | ||
| Paul Penepent, Head Accounting | ||
| Samir MD, Global Relations | ||
| Robert PharmD, Chief Officer | ||
| Klaus Moosmayer, Chief Ethics Risk and Compliance Officer, Member of the Executive Committee | ||
| Karen Hale, Chief Officer | ||
| Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee | ||
| Harry Kirsch, Chief Officer |
Novartis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 207.39 B | |||
| Shares Outstanding | 2.12 B | |||
| Shares Owned By Insiders | 3.74 % | |||
| Shares Owned By Institutions | 33.74 % | |||
| Price To Earning | 25.00 X | |||
| Price To Book | 3.22 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Novartis Pink Sheet
Novartis financial ratios help investors to determine whether Novartis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novartis with respect to the benefits of owning Novartis security.